Join These Global Investors at RESI JPM San Francisco 2023

17 Nov

By Joey Wong, Investor Research Analyst, Hong Kong BD, LSN

After a successful RESI Boston this fall, we are looking forward to bringing together more investors, strategic partners and early-stage, life science and healthcare companies from around the globe at our next in-person event, RESI JPM San Francisco, in the coming year. Whether you plan to travel to San Francisco in-person or participate virtually, RESI will be a great opportunity to kick off your business development or fundraising campaign for 2023.

With the conference starting in less than 2 months, our investor research team has been receiving a great deal of interest from investors every day, including both domestic investors and those based outside of the US. We are expecting 500+ global investors to join this conference, including large pharma/medtech, traditional VCs, family offices/private wealth, and angel groups.

Check out the registered investors for RESI SF below:

CI-11172022

Check RESI Website to See More Confirmed Investors

RESI-SF-2023-Banner-1100-wide

Tech Hub Exposure at RESI 2023

17 Nov

By Erika Wu, Business Development Manager, Global Tech Hubs, LSN

RESI JPM San Francisco will be in-person, January 10, followed by two-days of virtual partnering January 11 & 12. If you’re part of a tech hub, Life Science Nation (LSN)’s RESI is the hot spot for meeting with players in the earliest stages of the life science industry.

A key part of RESI is a global tech hub ecosystem of accelerators, incubators, non-profits, universities, tech transfer offices, and regional organizations who set up their early-stage life science startup constituents for success with their entrepreneurship journey. Recently, RESI has hosted tech hubs ranging from National Institute of Aging (NIA), Brisbane Economic Development Agency (BEDA), California Life Sciences (CLS), Massachusetts Medical Device Development Center (M2D2), Government of Ontario, and more.

Through RESI partnership, tech hub affiliated startups gain access to resources beyond partnering with investors and strategic partners. Resources such as the LSN Investor Database, Innovator’s Pitch Challenge (IPC), free workshops, and Entrepreneural Courses. These tools help develop compelling marketing materials, build meaningful relationships with investors and secure necessary early-stage funding.

At RESI San Francisco, tech hub organizations and their startups who’ve raised less than $2M can utilize:

  • 50% discount for startup registration (startup must be from LSN’s tech hub partners)
  • Complimentary tech hub staff registration
  • Exhibition space

If you’re a member of a tech hub or looking to add value to your members, reach out to see which offerings best fit your needs. From lab to clinic, and providers to patients, LSN is accelerating the growth and success of companies emerging from tech hubs.

For more information please contact Erika Wu, Business Development Manager, Global Tech Hubs of LSN.

RESI-SF-2023-Banner-1100-wide

Free Webinars for Fundraising Success

17 Nov

By Antoinette Lowre, Manager of Business Development, LSN

Life Science Nation (LSN) is now focusing our efforts towards planning our next in-person RESI event in San Francisco January 2023. RESI JPM San Francisco will be taking place during JP Morgan Healthcare week, the largest health care partnering week of the year.

The LSN team will be hosting FREE virtual workshops leading up to RESI JPM San Francisco to help our community of startups prepare for meeting with investors and strategic partners alike.

Check out and register for the LSN FREE Fundraising Workshops!

“Developing Your Global Target List of Investors”

Find tools to aid in your search for investors to reach out to who are a fit based on your company type.

Thursday, December 1, 11AM EST – Sign Up

“Preparing Your Non-Confidential Materials for JPM Healthcare Week”

As crucial as the innovative nature of your technology and value proposition is the way it is concisely conveyed through a professional set of non-confidential materials. Learn from our experts on how to organize your materials (ranging from pitch decks to executive summaries and tear sheets) to share with investors and partners at JPM Healthcare Week.

Tuesday, December 6, 12PM EST – Sign Up

“Tech Hub Exposure at RESI”

This workshop is designed for tech hub organizations ranging from accelerators, incubators, non-profits, universities, tech transfer offices, regional organizations, and more who set up their early-stage life science startup constituents for success with their entrepreneurship and fundraising journey. It will showcase the tools and resources that LSN makes available for Tech Hubs to help their startups who’ve raised less than $2M expand their outreach from Regional to Global, build a target list of investors and more.

Thursday, December 8, 2PM EST – Sign Up

“Successful Partnering”

Take a deep dive into your outreach campaign. Learn more about our proven successful strategy and how to craft your messages from your initial outreach and each follow up message after that.

  • Wednesday, December 14, 12PM EST – Sign Up
  • Partnering Tutorial – Tuesday, December 20, 2PM EST – Sign Up
  • Partnering Tutorial – Wednesday, December 28, 12PM EST – Sign Up

RESI-SF-2023-Banner-1100-wide

Hot Investor Mandate: Early-Stage Life Science Investment Group Seeks Opportunities Primarily in Therapeutics, Devices, and Diagnostics, and Can Invest in Financing Rounds Up to $20M

17 Nov

An active early-stage life science development group founded by a private company currently backs more than 15 programs and companies, based on technologies and assets developed internally or in-licensed from academic medical institutions. The most advanced company in the portfolio has completed a Series D round, and total investment across all technologies exceeds $150 million. The firm has a dual development strategy. The firm partners with academic inventors to found, manage, and develop companies to a point of exit or strategic partnering. When founding companies, the firm leverages non-dilutive grant funding where available alongside their investment group. The firm can also support early clinical-stage companies looking for financial and management support to perform clinical proof of concept studies; specifically a combination of investor funding and management support to round out the capabilities of the existing team. The firm and its affiliated investor groups have the ability to lead investment rounds of up to $20 million while also providing any required management support through its experienced team, including in preclinical, clinical and business development.

The firm invests across the biosciences space including Therapeutics, Diagnostics, and Medical Devices although the primary focus is on Therapeutics. The group is opportunistic in terms of subsectors and indications. Historically, the group has been active with companies developing novel therapeutics including drugs for defending against inhaled pathogenic threats, treatment of asthma, cancer, autoimmune diseases, and hearing loss, a biomedical assay platform technology, molecular diagnostics, antioxidant nanoparticles, robotic and imaging technologies, and cardiovascular devices.

The firm is interested in connecting with companies looking to generate clinical proof-of-concept data and that require funding as well as management support to complement the existing team. We are especially interested in companies that may have an interest in relocating to Houston.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Pharmaceutical Company Headquartered in Asia Seeks Novel Therapeutic Candidates in CNs, Immunology, Oncology, and More For Investment or In-Licensing

17 Nov

A pharmaceutical company based in Asia has annual sales of about $160 million with more than 600 employees. The firm’s current marketing portfolio are mostly made of branded products licensed in from overseas partners. For the R&D activity, the firm has several clinical pipelines in the area of CNS and oncology under clinical study in the US, Europe, and Korea. The firm is actively searching for innovative candidates and products around the world to incorporate into its pipeline. Additionally, the firm also seek promising biotech with innovative approach to add into its investment portfolio. The firm has ample experience across various types of partnerships with overseas companies and is flexible in terms of the business structure. The firm is interested globally, including world-wide major territories.

The firm is currently seeking promising novel therapeutic candidates to incorporate into its pipeline. The firm is also able to invest in a financing round, preferably series A or B. In terms of indications, the firm is interested in movement disorders, CNS, liver disease, and immunology. The firm is also interested in oncology indications (small molecule or biologics with novel MoA). The firm prefers assets both in late non-clinical development stage as well as in early clinical development stage. The firm is also interested in obtaining distribution rights for innovative treatment in Phase III or in marketing authorization process.

The firm is open to working with companies anywhere in the world, and has no set requirements for partners; the firm is able to work with virtual drug companies by leveraging the firm’s own capabilities and third-party relationships.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Venture Capital Firm with US and China Offices Invests in Seed to Series B Therapeutics, Devices, Diagnostics, and Life Science Tools

17 Nov

A venture capital firm based in USA with additional offices in China invests in early-stage life science ventures, from Seed to Series B, with Series A and Series B being the firm’s sweet spot. Typical size of investment ranges from $1-2M in seed stage companies, and $3-5M in venture round companies.  
The firm also has an advisory service that supports entrepreneurs to expand to the Chinese market, and the firm has multiple offices in China and needed expertise to support the entrepreneur’s vision. 

Currently, the firm is most interested in companies based in USA, Israel, and Western Europe, particularly companies in the Nordic region. 
 
The firm will consider therapeutics, medical devices, diagnostics, and life science tools. The firm is most interested in medical devices, and their interests include medtech and biotech combination products, novel methods of drug delivery, in vitro diagnostics (novel instruments and reagents), etc. The firm is interested in both 510K and PMA devices. Within therapeutics, the firm is more interested in clinical assets and typically do not look at pre-clinical companies unless the opportunity is compelling. Current main indication areas of interest for the firm are cardiovascular disease, oncology, and women’s health. 
 
The firm seeks to work with management teams who are passionate about their technology and dedicated to creating values for the larger community. Though the firm is able to support companies who are interested in entering the China market, having a China angle is not necessary for investment. The firm can act as either a lead or co-investor.


If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate: Strategic Fund of Biopharma Company Invests Up to $10M in Digital Health Technologies Targeting Oncology and Infectious Diseases

17 Nov

The strategic fund of a biopharmaceutical company based in Western Europe is aligned with the parent company’s strategy, focusing on technology investments related to oncology and infectious diseases. The firm has $150M under management and invests in the range of $1M – $10M per company. The Fund typically makes a first investment at Series A and currently aims to make 1-3 new equity investments a year.

The firm is mainly seeking digital health and healthcare IT investment opportunities at the pre-commercial or commercial stage that will either improve drug development or that will impact the patient journey (e.g., patient monitoring, digital therapeutics, clinical decision support systems) relating to oncology and infectious diseases.

The firm is very active and supportive of its portfolio companies. The Fund typically takes a board seat, and at times also an observer seat. The Fund is looking for management teams experienced in the domain of interest and with entrepreneurial experience.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

← Older Entries
Newer Entries →